

Contact the ASTRAL team

To request further information on the ASTRAL trial please use the details below.

Mrs Elizabeth Brettell, Trial Manager

+44 (0)121 415 9130

Miss Charmaine Meek, Trial Administrator

+44 (0)121 415 9132

Miss Gemma Ryan, Data Manager

+44 (0)121 415 9134

Miss N Ives, Senior Statistician

+44 (0)121 415 9113

Main BCTU switchboard: 0121 415 9100

Fax: +44 (0)121 415 9135

Email: renal-trials@contacts.bham.ac.uk (<mailto:renal-trials@contacts.bham.ac.uk>)

Useful links

[Kidney Research UK](http://www.kidneyresearchuk.org/home.php)

(<http://www.kidneyresearchuk.org/home.php>)

[The Journal of Renovascular Disease](http://www.journalrenovascularisease.com/) (<http://www.journalrenovascularisease.com/>)

[British Society of Interventional Radiology](http://www.bsir.org/) (<http://www.bsir.org/>)

[UK Interventional Radiology Course](http://www.ukirc.org.uk/) (<http://www.ukirc.org.uk/>)

Find out more information about our other renal trials and the University of Birmingham Clinical Trials Unit below:

BCTU

(<http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/index.aspx>) The University of Birmingham Clinical Trials Unit (BCTU) is a Research Unit within the School of Medicine specialising in the design, conduct and analysis of clinical trials.

PEXIVAS

(<http://www.bctu.bham.ac.uk/pexivas/>) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomised controlled trial.

[PREDNOS](http://www.bctu.bham.ac.uk/prednos/) (<http://www.bctu.bham.ac.uk/prednos/>)

PREDNOS is a national multi centre randomised double blind trial of long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome.

[GloMY](http://www.bctu.bham.ac.uk/GloMY/) (<http://www.bctu.bham.ac.uk/GloMY/>)

GloMY is a national, multi-centre, randomised controlled open-label pilot trial of Myfortic plus short course steroids versus standard care in patients with proteinuric primary focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).

[PREDNOS 2](http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/renal/prednos2/index.aspx) ([/research/activity/mds/trials/bctu/trials/renal/prednos2/index.aspx](http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/renal/prednos2/index.aspx))

PREDNOS 2 is a phase III randomised parallel group, placebo-controlled, double-blind trial of short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome.

[STOP-ACEi](http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/renal/STOPACEi/index.aspx) ([/research/activity/mds/trials/bctu/trials/renal/STOPACEi/index.aspx](http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/renal/STOPACEi/index.aspx))

STOP-ACEi is a multi-centre, randomised controlled trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced kidney disease.